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Tauopathyprotein Ser/Thr phosphatase which acts on tau in vivo, is a heterodimer of a
catalytic subunit, calcineurin A, and a regulatory subunit, calcineurin B, and is unique in being regulated by
calmodulin. Here, we ﬁnd that both subunits of calcineurin bind tau, and calmodulin interferes with the
association between calcineurin and tau. The domains of both subunits of calcineurin and tau involved in
binding are mapped. We also investigate the functional consequences of the interactions between both
subunits of calcineurin, tau and calmodulin, and reveal the interactions affect dephosphorylation of tau by
calcineurin and contribute to the balance of phosphorylation and dephosphorylation of tau in vivo. Our
ﬁndings may be of potential signiﬁcance in neuronal physiology and also in neurodegenerative disorders.
They shed some light on how the interactions might control the phosphorylation state of tau under
physiological conditions, and provide new insights into the treatment of tauopathies such as Alzheimer's
disease.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionCalcineurin (CN), also termed protein phosphatase 2B (PP-2B), is
the only known protein Ser/Thr phosphatase whose activity is
regulated by calmodulin (CaM) [1]. CN is involved in many critical
physiological and pathological processes, including T-cell activation,
apoptosis, ion channel regulation, cardiac myocyte hypertrophy and
Alzheimer's disease (AD) [2,3].
CN has a very narrow substrate speciﬁcity in vivo, in contrast to
other phosphatases. A number of potential neuronal target proteins
for CN have been suggested, such as tau, whose abnormal phosphor-
ylation is a key pathological characteristic of AD [4]. As the major
microtubule (MT)-associated protein (MAPs) in vivo, the most
important function of tau is to modulate the assembly, behavior and
spatial organization of microtubules [5,6]. But tau is also able to
associate with many important cellular components, and participates
in many key physiological processes [7–9]. It was shown previously
that tau associate with protein phosphatase 2A (PP2A), a homologous
protein Ser/Thr phosphatase of CN, via the former's MT-bindinghibitory domain of CNA; BBH,
combinant single chain CNA–
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l rights reserved.domain; as a consequence, MTs are able to inhibit the tau phosphatase
activity of PP2A [10]. Although the PP2A holoenzyme associates with
tau, the separate A, B, C subunits and the AC dimer are unable to do so
[11]. As a heterodimeric protein, CN consists of a 61 kDa catalytic
subunit A (CNA) and a 19 kDa regulatory subunit B (CNB) [12]. It is
interesting to know whether just like PP2A, both subunits of CN are
required for associating with tau or not, and what role CaM plays in
the interaction between CN and tau.
In the present study, we found that not only CNA, but also CNB
bound tau, and CaM impaired the association between CNA–CNB and
tau. The domains involved in the associations involving tau, CNA and
CNB were located. We also investigated the functional consequences
of the interactions between CNA, CNB, tau and CaM, and revealed how
the interactions affected dephosphorylation of tau by CN.
2. Materials and methods
2.1. Materials
The following were from our laboratory collection: cDNAs for
human tau40, rat CNAα and its truncation mutants, rat CNB and its
truncation mutants, and human CaM; also the vectors pGEX-4T-3 and
pET-31b(+) as well as the PC12 rat pheochromocytoma cell line. The
Bal b/c mice were from the animal center of Peking University. RII
peptide was obtained from BioMoL Research Laboratories Inc.
(Plymouth, USA). [γ-32P] ATP was from Beijing Furi Biologic and
Medicinal Engineering Co. (Beijing, China). The catalytic subunit of
cAMP-dependent protein kinase was obtained from Promega Chemi-
cal Co. (Madison, USA). Rabbit polyclonal anti-tau, mouse polyclonal
anti-CNA and anti-CNB, CNB–sepharose-4B and CaM–sepharose-4B
were produced in our laboratory. Fluoresceinisothiocynate (FITC)-
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nate (TRITC)-conjugated goat anti-mouse IgG and peroxidase-con-
jugated goat anti-rabbit and horse anti-mouse IgGwere obtained from
Jackson ImmunoResearch Laboratories Inc. (West Grove, USA). Rabbit
polyclonal anti-MAP2 and protein G plus-agarose beads were from
Santa Cruz Biotechnology Inc. (Santa Cruz, USA). Glutathione-agarose
beads and His·bind puriﬁcation columns were from GE Healthcare
Bio-Sciences AB (Uppsala, Sweden). Chemiluminescent substrate kits
were obtained from Pierce Chemical Co. (Rockford, USA). All other
reagents were of standard laboratory grade and the highest quality
available from commercial suppliers.
2.2. GST pull-down assay
Glutathione-agarose beads (50 µl each) coated with GSTor GST-tau
were incubatedwith 100 µl aliquots of lysates of cells including CNA orFig.1. Tau binding properties of CNA and CNB. (A, B) CNA-binding (A) and CNB-binding (B) of G
alone, CNA or CNB incubated with GST-tau, CNA or CNB incubated with GST control, an
immunoprecipitated from fresh mouse brain extracts with anti-tau antibody. The resulting a
CNB antibody (D). The sample order is brain extract control, brain extracts precipitated by ant
CaM, and control omitting anti-tau antibody. (E, F) Immunoﬂuorescence staining of culture
shown. Tau was detected with FITC-conjugated goat anti-rabbit IgG (green) and CNA or CNBw
by yellow staining. (G, H) MAP2 was immunoprecipitated from fresh mouse brain extracts
immunoblotted using anti-CNA (G) and anti-CNB antibody (H). The sample order is brain e
anti-MAP2 antibody. Scale bar, 10 µm. All immunoblot and immunoﬂuorescence images areCNB (1mg/ml protein in buffer A [50mM Tris–HCl, 50mMNaCl, 1 mM
Ca2+, 0.1% β-ME, 0.2 mM PMSF, pH 7.4]) for 3 h at 4 °C with end-over-
end shaking. The beads were recovered by centrifugation and washed
three times with buffer B (50 mM Tris–HCl (pH 7.4), 100 mM NaCl,
1 mM Ca2+, 0.1% β-ME, 0.2 mM PMSF). They were mixed with 50 µl
SDS-PAGE sample buffer, boiled, and centrifuged, and 10 µl samples
were immunoblotted with anti-CNA or anti-CNB antibody.
2.3. Immunoprecipitation
Mouse brain extract (0.5 ml) or cell lysates (0.1 ml) containing
1 mg/ml protein in buffer A were precleared with 25 µl protein G
plus-agarose beads equilibrated in buffer A, and divided in half. To
one half, 25 µl preimmune serum was added, and to the other, 25 µl
anti-tau, anti-MAP2, anti-CNA or anti-CNB antiserum. Both halves
were shaken end-over-end at 4 °C. After 4 h of shaking, 25 µl proteinST-tau were detected by pull-down experiments. The sample order is CNA alone or CNB
d control cell lysates without CNA or CNB incubated with GST-tau. (C, D) Tau was
nti-tau antibody immune complexes were immunoblotted using anti-CNA (C) and anti-
i-tau antibody, brain extracts precipitated by anti-tau antibody in the presence of excess
d PC12 cells for tau and CNA (E) or CNB (F). Separate staining and merged images are
as detected by TRITC-conjugated goat anti-mouse IgG (red). Co-localization is indicated
with anti-MAP2 antibody. The resulting anti-MAP2 antibody immune complexes were
xtract control, brain extracts precipitated by anti-MAP2 antibody, and control omitting
based on at least three independent experiments; representative examples are shown.
Fig. 2. Localization of the interacting regions within tau, CNA and CNB. (A) Localization of CNA and CNB-binding domains within tau. Lysates of cells expressing tau or its truncation
mutants were mixed with lysates of cells expressing CNA or CNB, and precipitated with anti-tau. A schematic diagram of the tau species used in the assay, and the immunoblot
analysis of the precipitates with anti-CNA or anti-CNB are shown. (B) Localization of tau binding domain within CNA. Lysates of cells expressing tau were mixed with lysates of cells
expressing CNA or its truncation mutants, and precipitated with anti-CNA. A schematic diagram of the CNA species used in the assay and the immunoblot analysis of the precipitates
with anti-tau are shown. (C) Localization of tau binding domainwithin CNB. Lysates of cells expressing tauweremixedwith lysates of cells expressing CNB, DN or DC, and precipitated
with anti-CNB. A diagram of the CNB species used in the assay and the immunoblot analysis of the precipitates with anti-tau are shown. All immunoblot images are from at least three
independent experiments; a representative example is shown.
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each half, and shaking was continued for another 1 h. The protein G
plus-agarose beads were collected by centrifugation, washed ﬁve
times with ice-cold buffer B, and immunoblotted using anti-CNA,
anti-CNB or anti-tau antibody.
2.4. Immunoﬂuorescence staining
PC12 cells were immunoﬂuorescently stained as described [13]
except for some modiﬁcations. The cells were grown on polylysine
glass coverslips. For ﬁxation without detergent extraction, the cells
were washed with PBS (10 mM phosphate buffer, pH 7.4, 137 mM
NaCl), and incubated with ice-cold methanol for 5 min. After
washing ﬁve times with PBS, they were incubated with incubation
buffer (5% defatted milk powder in PBS) at 37 °C for 1 h. Anti-tau
antibody and anti-CNA or anti-CNB antibody were added, and
incubation continued for another 2 h at 37 °C. The cells were washed
three times with PBS, and then incubated with FITC-conjugated goat
anti-rabbit IgG and TRITC-conjugated goat anti-mouse IgG in
incubation buffer for 30 min at 37 °C. After washing three times
with PBS, the coverslips were mounted in 90% (vol/vol) glycerol and
10% (vol/vol) PBS, and the cells were photographed with an Olympus
ﬂuorescence microscope.
2.5. CNB and CaM afﬁnity chromatography
CNB–sepharose-4B or CaM–sepharose-4B afﬁnity chromatogra-
phy medium was incubated with lysates of cells expressing protein I
(tau or CNA in buffer A [50 mM Tris–HCl, 50 mM NaCl, 1 mM Ca2+,
0.1% β-ME, 0.2 mM PMSF, pH 7.4]) for 2 h at 4 °C with end-over-end
shaking. The sepharose-4B was recovered by centrifugation, washed
three times with ice-cold buffer A and incubated with lysates of
cells expressing protein II (tau, CNB or CaM in buffer A) for 2 h at
4 °C with end-over-end shaking. The sepharose-4B was again
recovered by centrifugation, washed three times with ice-cold buffer
A and incubated with lysates of cells expressing protein III (tau) for
2 h at 4 °C with end-over-end shaking, washed as before. It was
then mixed with 50 µl SDS-PAGE sample buffer, boiled, and
centrifuged, and a 10 µl sample was immunoblotted with anti-tau
antibody.Fig. 3. Effects of CaM on tau binding capacity of CNA–CNB. (A) Tau binding detected by co-imm
agarose pre-incubated with anti-CNA and CNA in the middle three lanes, and the liquid phas
followed by tau. The ﬁnal lane is same as the 4th lane except that anti-CNAwas omitted. (B) Ta
The solid phasewas CNB–sepharose-4B in all the other lanes, and the liquid phases were as fol
Tau binding detected by CaMafﬁnity chromatography. Theﬁrst lanewas tau alone. Solid phase
tau; CNA added ﬁrst, followed by tau; CNA followed by CNB, followed by tau. (D) Tau bindi
precipitated by tau; control cell lysate without CBA precipitated by tau. All immunoblot imag2.6. Protein phosphatase assay
RII peptide was 32P-labeled using the catalytic subunit of cAMP-
dependent protein kinase as described [14]. Radioactive labeling of tau
was performed in the sameway except that incubationwas prolonged
to 4 h. In these conditions tau was labeled at several main sites
including Ser214, Ser262, Ser324, Ser356 etc [15]. The 32P-labeled RII
peptide and tau were used to measure CN phosphatase activity as
described [16] with some modiﬁcations. Puriﬁed CNA was diluted in
2×assay buffer (100 mM Tris–HCl, 0.2 mg/ml BSA, 1 mM DTT and
1mMMn2+, pH 7.4; with or without 0.2 mM CaCl2, 0.6 µM CaM and/or
0.2 µM CNB). 10 µl of diluted enzyme solutionwas mixed with 10 µl of
10 µM 32P-labeled RII peptide or tau dissolved in milliQ water, and
incubated for 10 min at 30 °C. The reaction was terminated by adding
180 µl of 83.3 mM H3PO4 and the released inorganic 32P was
quantiﬁed by liquid scintillation counting. Phosphatase activities are
expressed as picomoles of phosphate released/mg of protein/min at
30 °C.
3. Results and discussion
3.1. CNB as well as CNA binds tau
To illuminate how CN associates with tau, we investigated the
interaction between CNB and tau, as well as between CNA and tau,
using GST pull-down assays. We were surprised to ﬁnd that not only
CNA, but also CNB was precipitated with GST-tau from the respective
cell lysates (Fig. 1A, B). To gain more support for the above result, we
immunoprecipitated tau from fresh mouse brain extracts. Both CNA
and CNB were immunoprecipitated with tau (Fig. 1C, D). Further, we
showed by immunoﬂuorescence microscopy that endogenous CNA
and CNB colocalized with tau in PC12 cells (Fig. 1E, F). Evidently both
subunits of CN are able to associate with tau in vitro and in vivo, which
are distinct from the association between PP2A and tau.
Tau related MAPs, MAP2 is also the known physiological substrate
of CN [17]. In order to test the speciﬁcity of tau binding to CN, the
interaction between both subunits of CN andMAP2was studied by co-
immunoprecipitation. MAP2 binds to CNA, but not to CNB (Fig. 1G, H),
which are different from the above exposed association between tau
and CN. This suggests that tau binding to CNB is of tau speciﬁcity.unoprecipitation. The ﬁrst lane is tau alone. The solid phase consisted of protein G plus-
es were as followings: tau; CNB added ﬁrst, followed by tau; CNB followed by CaM, and
u binding detected by CNB afﬁnity chromatography. The ﬁrst lane consisted of tau alone.
lowings: tau; CNA added ﬁrst, followed by tau; CNA followed by CaM, followed by tau. (C)
swere all CaM–sepharose-4B in the other lanes, and the liquid phaseswere as followings:
ng of CBA detected by co-immunoprecipitation. The sample order was CBA alone; CBA
es are from at least three independent experiments; representative examples are shown.
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To localize the CNA and CNB-binding domains within tau, we cons-
tructed tau truncation mutants in three regions that are responsible for
binding tau to other proteins [18,19]: the PF (projection fragment region,
1–197 Aa), PRB (proline-rich and basic region, 151–244 Aa) and MBR
(microtubule binding repeats domain, 244–368 Aa). Immunoprecipita-
tion of tau and its truncationmutants showed that the PRB is involved in
the interaction between CNA and tau and that the MBR is required for
CNB-binding by tau, indicating that CNB and the MTs interact with the
same functional domain of tau (Fig. 2A). It has been observed previously
that, in the presence of Ca2+, the CNB-homologous protein, CaM, also
binds weakly to the MBR of tau [20].
CNA contains four functional domains: a catalytic domain (CNAa), a
CNB-binding domain (BBH), a CaM-binding domain (CBD), and an
autoinhibitory domain (AID) [21]. The BBH is responsible for the
interaction between CNA and RII peptide [16]. In order to determine
which functional domains of CNA participate in tau binding we
immunoprecipitated CNA and its three truncation mutants: CNAa,
CNAab (CNAa-BBH) and CNAabc. The results in Fig. 2B show that
CNAabc and CNA bind tau with almost equivalent efﬁciencies. By
comparison, CNAabwas clearly less able to bind tau, and no binding of
CNAa was detected. These observations indicate that the CBD, in
addition to the BBH, is involved in the binding of tau to CNA.
CNB is composed of two global Ca2+ binding domains: DN (N-
terminal domain) and DC (C-terminal domain), each of which containsFig. 4. Activity assays and kinetic analyses of CNA and CNAabc. (A, B) With RII peptide or t
presence of CNB or CaM. (C, D) The Km (C) and Kcat (D) of CNA for RII peptide and tau were de
for tau were determined in the absence or presence of CNB and/or CaM. (F) The Kcat /Km of CN
Error bars are s.d. (n=3).two Ca2+-binding EF-hand motifs [22]. DN and DC were immunopre-
cipitated to localize the tau binding domainwithin CNB. Fig. 2C shows
that the DN domain is responsible for tau binding of CNB. It was
shown previously that the DC domain played a central role in the
interaction between CNB and CNA [23], which suggests that CNA and
tau do not compete signiﬁcantly for binding to CNB.
3.3. CaM impairs binding between CNA–CNB and tau
To clarify the role of CaM in the interaction between CN and tau, we
carried out interaction experiments involving CaM, CNA, CNB and tau.
Co-immunoprecipitation of CNA and tau showed that their interaction
was almost unaffected by CNB, but CaM almost completely blocked
the interaction between CNA–CNB and tau (Fig. 3A). CNB afﬁnity
chromatography revealed that both CNB–sepharose-4B itself and
CNB–sepharose-4B pre-incubated with CNA were able to bind tau.
However, when the CNA–CNB–sepharose-4B complex formed was
incubated with CaM, the resulting CNA–CNB–CaM complex failed to
bind tau (Fig. 3B). CaM afﬁnity chromatography also showed that the
presence of CaM impaired tau binding by CNA–CNB (Fig. 3C). We then
used the recombinant single chain CaM–CNB–CNA complex (CBA)
thought to have uniform structure with native CNA–CNB–CaM ternary
complex [24] to conﬁrm the above results. Fig. 3D shows that no
interaction between CBA and tau was detected by co-immunopreci-
pitation. In addition, tau failed to co-immunoprecipitate with CNA or
CNB in mouse brain lysates in the presence of excess CaM (Fig. 1C, D).au as substrate, CNA (A) and CNAabc (B) activities were determined in the absence or
termined in the absence or presence of CNB and/or CaM. (E) The Km and Kcat of CNAabc
A for RII peptide and tau was determined in the absence or presence of CNB and/or CaM.
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CNB–CaM ternary complex impedes the interaction of CNA and CNB
with tau. It may be that the association between CNA, CNB and CaM
sterically blocks their respective sites for tau binding.
3.4. Protein interactions affect dephosphorylation of tau by CN
Previously, the abnormal phosphorylation of tau at multiple Ser/
Thr sites was attributed to defective CN activity in early AD [3,25–27].
The above results revealed that both subunits of CN associated with
tau, and CaM impaired the binding between CN and tau. It is
interesting to know whether the interactions between CNA, CNB, tau
and CaM participate in regulating the phosphorylation levels of tau
under normal physiological or pathological conditions in vivo. In
vitro, with RII peptide or p-nitrophenyl phosphate as substrate, the
catalytic and regulatory mechanisms of CN have been investigated.
However, only by using tau as substrate, would it be possible to
establish the actual in vivo relationship between CN and tau
phosphorylation.
By a series of chromatographic steps, we puriﬁed, to electro-
phoretic purity, recombinant tau, CNA, and CNAabc (which contains
CNAa, the BBH and the CBD of CNA), as well as recombinant CNB and
CaM (data not shown).
We investigated the potential activating effects of CNB and CaM
on the activity of CNA and its truncation mutant CNAabc with
phosphorylated RII peptide and tau as substrates. In agreement with
previous results [16] we found that, with RII peptide as substrate,
CNB activated CNA 19.4 fold and CaM activated it 2.8 fold. With tau
as substrate, CaM activated CNA 3.8 fold, which was similar to the
stimulation with RII peptide as substrate, but CNB only activated CNA
1.7 fold (Fig. 4A). This indicated that using tau as substrate, the
regulatory effect of CNB on CNA differed with that using RII peptide as
substrate. Maybe, it is the interaction between CNB and tau that leads
to the different regulatory effect. The results with CNAabc conﬁrmed
this notion (Fig. 4B).
In order to understandhow the interactions between CNA, CNB, tau
and CaM affect the dephosphorylation of tau by CN, we performed
kinetic analyses of the afﬁnity of CN for RII peptide and tau. Interes-
tingly, the Km of tau for CNA on its ownwas a mere 0.5 µM, lower than
its Km for the CNA–CNB, CNA–CaM or CNA–CNB–CaM complex. These
data were quite different from those obtained with RII peptide. They
suggested that CNB and CaM are not required for the association
between CNA and tau, which conﬁrms the results of the above protein
interactions. The association is very strong, about 700 fold stronger
than that between CNA andRII peptide (Fig. 4C). In addition, the kinetic
analyses indicated that CNB reduced the Km of CNA for RII peptide, and
increased the Kcat of CNA. However, CNB alone had hardly any effect on
the kinetic constants of CNA for tau (Fig. 4C, D). Our kinetic analyses
also indicated that CNB togetherwith CaMdecreased the Km of CNA for
RII peptide. In contrast, the Km for tau was increased (Fig. 4C), which
conﬁrmed the impairment of CaM for the association between CN and
tau. The kinetic analyses of the interactions of CNAabc and tau
conﬁrmed the above results (Fig. 4E). These results thus demonstrate
that the associations between CNA, CNB, tau and CaM affect the
regulatory actions of CNB and CaM on CNA.
We are surprised to ﬁnd that the efﬁciency (Kcat /Km) with which
CN dephosphorylates tau is constant, about 4000 M−1·−1, in the
absence or presence of CNB and/or CaM (Fig. 4F), which may
contribute to the balance between in vivo phosphorylation and
dephosphorylation of tau under normal physiological conditions in
vivo. Although CNB and CaM play different roles in the above
interactions, both of them are responsible for the constant efﬁciency.
Our ﬁndings may be of potential signiﬁcance not only in neuronal
physiology, but also in neurodegenerative disorders. In AD, the defect
in CN's ability to dephosphorylate tau has been attributed to a loss of
CNA activity [28,29]. However, based on the above results we thinkthat changes in the ability of CNB or the CNA–CNB–CaM complex to
bind to tau may also play a role. Correcting any binding defects should
contribute to restoring CN's ability to dephosphorylate tau. Further-
more, this effect could be speciﬁc because it should not inﬂuence the
ability of CN to dephosphorylate other substrates in vivo. Thus, the
speciﬁc interactions between CNB and tau, as well as between the
CNA–CNB–CaM complex and tau are promising targets for new
therapeutic drugs against tauopathies such as AD.
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